GRANT NUMBER:  DAMD17-95-1-5022

TITLE:  Environmental Exposures, Genetic Polymorphisms and p53 Mutational Spectra in a Case-Control Study of Breast Cancer

PRINCIPAL INVESTIGATOR(S):  Peter G. Shields, M.D.

CONTRACTING ORGANIZATION:  National Cancer Institute
Bethesda, Maryland  20892-4255

REPORT DATE:  January 1996

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland  21701-5012

DISTRIBUTION STATEMENT:  Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Environmental Exposures, Genetic Polymorphisms and P53 Mutational Spectra in a Case-Control Study of Breast Cancer

Peter G. Shields, M.D.

National Cancer Institute
Bethesda, Maryland 20892-4255

Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick
Frederick, Maryland 21702-5012

Approved for public release; distribution unlimited

The original goal of this project is to determine the frequency of genetic polymorphisms for carcinogen metabolism and the p53 mutational spectra in a previously conducted breast cancer study designed to assess nutritional risk factors, seeking to identify risk factors related to inheritable susceptibilities and chemical etiologies. We have determined that the NAT2 slow acetylator genotype and cigarette smoking is a risk factor for postmenopausal, but not premenopausal, women. Rapid acetylators are at risk if they consume processed meats. There was no association for CYP2E1 and breast cancer. Other genetic polymorphisms are either in progress or are completed (CYP2D6, MEH, ADH, APOE). Other parts of this study, including the p53 mutational spectra analysis and the ancillary studies corroborate these findings and develop smoking prevention strategies are currently in progress. Thus far, the findings of these studies are important because they are identifying new etiologies for breast cancer where behavior modification would lead to a decreased risk.

breast cancer

Unlimited

11

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)

Prescribed by ANSI Std. Z39-18

298-192
The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important
that this information be consistent with the rest of the report, particularly the cover and title page.
Instructions for filling in each block of the form follow. It is important to stay within the lines to meet
optical scanning requirements.

Block 1. **Agency Use Only (Leave blank).**

Block 2. **Report Date.** Full publication date including day, month, and year, if available (e.g. 1
Jan 88). Must cite at least the year.

Block 3. **Type of Report and Dates Covered.** State whether report is interim, final, etc. If
applicable, enter inclusive report dates (e.g. 10
Jun 87 - 30 Jun 88).

Block 4. **Title and Subtitle.** A title is taken from the part of the report that provides the most
meaningful and complete information. When a report is prepared in more than one volume,
repeat the primary title, add volume number, and
include subtitle for the specific volume. On
classified documents enter the title classification
in parentheses.

Block 5. **Funding Numbers.** To include contract
and grant numbers; may include program
element number(s), project number(s), task
number(s), and work unit number(s). Use the
following labels:
- C - Contract
- G - Grant
- PE - Program
- WU - Work Unit
- EA - Element
- AC - Accession No.

Block 6. **Author(s).** Name(s) of person(s)
responsible for writing the report, performing
the research, or credited with the content of the
report. If editor or compiler, this should follow
the name(s).

Block 7. **Performing Organization Name(s) and
Address(es).** Self-explanatory.

Block 8. **Performing Organization Report
Number.** Enter the unique alphanumeric report
number(s) assigned by the organization
performing the report.

Block 9. **Sponsoring/Monitoring Agency Name(s)
and Address(es).** Self-explanatory.

Block 10. **Sponsoring/Monitoring Agency
Report Number.** (If known)

Block 11. **Supplementary Notes.** Enter
information not included elsewhere such as:
Prepared in cooperation with...; Trans. of...; To be
published in... When a report is revised, include
a statement whether the new report supersedes
or supplements the older report.

Block 12a. **Distribution/Availability Statement.**
Denotes public availability or limitations. Cite any
availability to the public. Enter additional
limitations or special markings in all capitals (e.g.
NOFORM, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution
Statements on Technical
Documents."

**DOE** - See authorities.


**NTIS** - Leave blank.

Block 12b. **Distribution Code.**

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories
from the Standard Distribution for
Unclassified Scientific and Technical
Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

Block 13. **Abstract.** Include a brief (Maximum
200 words) factual summary of the most
significant information contained in the report.

Block 14. **Subject Terms.** Keywords or phrases
identifying major subjects in the report.

Block 15. **Number of Pages.** Enter the total
number of pages.

Block 16. **Price Code.** Enter appropriate price
code (NTIS only).

Block 17. **- 18. Security Classifications.** Self-
explanatory. Enter U.S. Security Classification in
accordance with U.S. Security Regulations (i.e.,
UNCLASSIFIED). If form contains classified
information, stamp classification on the top and
bottom of the page.

Block 20. **Limitation of Abstract.** This block must
be completed to assign a limitation to the
abstract. Enter either UU (unlimited) or SAR (same
as report). An entry in this block is necessary if
the abstract is to be limited. If blank, the abstract
is assumed to be unlimited.

*U.S.GPO.1991-0-305-778*
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature]

[Date]
Table of Contents

Front Cover ...... 1
SF298 ............. 2
Foreword .......... 3
Table of Contents ... 4
Introduction ........ 5
Body ............... 6
Conclusions .......... 10
References ........... 11
INTRODUCTION

The original goal of this project is to determine the frequency of genetic polymorphisms for carcinogen metabolism and the p53 mutational spectra in a previously conducted breast cancer study designed to assess nutritional risk factors, seeking to identify risk factors related to inheritable susceptibilities and chemical etiologies. The workscope was subsequently expanded to include the same goals, but for other epidemiological studies of breast cancer, and to perform studies of breast metabolism, p53 and smoking (including smoking cessation). We were awarded to examine a variety of risk factors (hormonal and non-hormonal; environment and diet; carcinogens and anticarcinogens) in relationship to p53 mutations and breast cancer with genetic polymorphisms as effect modifiers. The frequency of genetic polymorphisms themselves in relation to breast cancer and to p53 mutations are being determined.

A population-based case-control study of breast cancer was conducted between 1986 to 1991; blood and tissue have been stored. There were 371 postmenopausal and 301 premenopausal women with breast cancer and 438 and 316 age-matched controls, respectively. Genotyping for GSTM1, CYP1A1, CYP2D6, CYP2E1, APOE, aldehyde dehydrogenase, glutathione-S-transferase theta (GSTT) and N-acetyltransferase 1 and 2 is being determined for all subjects. The p53 mutational spectra is being determined for informative cases, who will be identified by single stranded conformational polymorphism analysis and immunohistochemical staining. Persons with mutations will be categorized by mutation and hypothesized chemical etiology will be compared to persons with other types of p53 mutations (four for each case) and also to controls without cancer (ten for each case). Odds ratios and logistic regression will address the association of genetic polymorphisms and exposures as a risk for p53 mutation and breast cancer, adjusting for other risk factors. We also will examine effect modification for other risk factors by genetic polymorphisms.

The current workscope has been expanded to perform additional studies relating to findings in the first year of the award, specifically as they relate to smoking, smoking-related
carcinogens and breast cancer. Thus, we are culturing human breast epithelial cells and examining the rate of adduct formation from cigarette-smoke carcinogens, as well as the p53 and apoptosis response. Interindividual variation will specifically be addressed. The purpose of these studies is to corroborate our epidemiological findings. We will also reproduce our findings in additional epidemiological studies. Finally, we will examine nicotine addiction and genetic risk factors for addictive behaviors, in the context of a smoking cessation project, in order to identify smoking cessation strategies that will reduce the incidence of breast cancer in susceptible populations.

BODY

1. Collection of Tissue Samples and Tissue Preparation

- DNA has been extracted from blood clots of 300 premenopausal cases and additionally, we identified 80 additional postmenopausal cases for which we now have extracted the DNA.

- Tumor blocks for 93 cases have been obtained and sectioned. An additional 200 have been identified.

- A mechanism for receiving fresh breast tissues from autopsy cases and reduction mammoplasties is in place. We have received four to date, 2 of which are suitable for cell culture. Additionally, we have collected 120 frozen breast tissues (100 female and 20 male).

- Collection of blood samples from 500 persons enrolled in a smoking cessation project and non-smokers have been collected. 100 samples have been extracted to date.

2. Genetic Polymorphism analysis

- NAT2 genotyping was completed for all premenopausal and additional postmenopausal cases. We found that there was a significant association of breast cancer and smoking for postmenopausal women who are slow acetylators. The risk was greatest for smoking one
pack per day, and intensity of smoking was a greater risk factor than duration. We performed several types of analyses including a case-series analysis and a smoking-matched nested case control study. All results were consistent, with odds ratios of approximately 8.0 in the highest quartiles of smoking. However, we did not find a smoking effect for premenopausal women. Whether this is due to different risk factors for what are essentially different diseases (pre- versus postmenopausal), latency or different capacities for metabolism remain to be determined. The biological mechanism for this finding is likely and impaired capacity to detoxify aromatic amines. Laboratory studies confirming this finding, the analysis in other study groups and a study of smoking addiction are currently being conducted (see below). A manuscript summarizing these findings have been submitted to the Journal of the American Medical Association.

We also have completed the analysis of NAT2 and diet. We found that there was risk of breast cancer in premenopausal women who were rapid acetylators and consumed processed meats. There was no increased risk for consumption of red meat, poultry or fish. No association was found for postmenopausal women. The biological basis for this finding is likely related to the consumption of heterocyclic amines, and laboratory studies are now in progress to further investigate this. A manuscript has been submitted to Cancer Research.

- Apolipoprotein E is involved in the production of VLDL and other parts of cholesterol metabolism. Several studies have related low cholesterol levels to breast cancer risk. The apoE gene is polymorphic, where some variants raise cholesterol levels and others lower them. We therefore measured apoE genotypes in both the pre- and postmenopausal women. The statistical analysis is currently being conducted.

- Alcohol consumption has been associated with breast cancer risk. Alcohol is metabolized in humans via aldehyde dehydrogenase to a reactive acetaldehyde. It is unknown, what if any, component of the alcoholic
beverage, or a metabolite, is related to breast cancer. To further refine the risk and assess metabolism, we are currently measuring a polymorphic site within ADH that lowers activity by 40%. The assays for the postmenopausal women are completed and we are currently assaying the premenopausal women.

- Our previous results indicated that a polymorphism in cytochrome P4501AI is related to breast cancer in persons with low tobacco use. There also was a non-significant trend for younger postmenopausal women. Both of the enzymes are involved in the activation and detoxification, respectively, of polycyclic aromatic hydrocarbons. Another enzyme involved in this pathway is microsomal epoxide hydrolase. There are two polymorphic sites that result in a decrease of activity by 40%. We are currently measuring this polymorphism and have approximately 100 postmenopausal cases completed.

- Cytochrome P450IID6 has been associated with lung cancer and breast cancer. Its metabolic substrate is unknown, but it may be a tobacco-specific nitrosamine. We are measuring the activity of this gene by PCR. Thus far, assays (4 different polymorphic sites) are completed for the postmenopausal women and 3 of 4 sites are completed for the premenopausal women.

- Cytochrome P450IIE1 is involved in the metabolic activation of carcinogenic N-nitrosamines. There is a polymorphism located in the non-coding region of the gene that has been associated with lung cancer. This site was measured in all pre- and postmenopausal women. We have thus far found that there was no relationship to family history or smoking. A manuscript summarizing this data has been submitted to Molecular Carcinogenesis. The data in relation to diet is now being studied.

3. P53 Mutational Spectra Analysis

- Blocks have been obtained and are being sectioned. We have identified appropriate controls to ensure quality.
control and no contamination of wild-type DNA. We have identified these controls from lung cancer samples. There are 20 controls that contain mutations in each of the 4 exons of interest. We have also prepared blocks of cell lines with known p53 mutations, which also will be used as controls. The PCR of samples is currently beginning.

4. Ancillary Studies

- We have developed the technique in our laboratory, based upon previously published methods, to isolate breast epithelial cells and culture them in a sterile environment. Thus far we have obtained four tissues and were successful in two. In these cells, we have determined that 4-aminobiphenyl is metabolically activated through cytotoxicity experiments. We plan to obtain viable cultures from 50 women, and examine the interindividual variation in relation to NAT2 acetylation. DNA adducts will be measured using the postlabeling ADAM procedure and radiolabeled compounds will also allow us to measure adducts using accelerator mass spectroscopy. We also will examine the p53 response and apoptosis. The studies also will utilize heterocyclic amines and benzo[a]pyrene.

- A collaboration has been initiated with Melissa Bondy, Ph.D. at the MD Anderson Cancer Center to perform a case-series study of NAT2 and smoking in women with breast cancer. We will analyze Caucasians, to follow-up our earlier results and also include Hispanics and African Americans. We are targeting a total of 400 samples. Genotyping will be performed from paraffin-embedded tissues. Samples are currently being collected.

- We have entered into a collaboration with Caryn Lehrman at Georgetown University and Neil Caporaso of the Genetic Epidemiology Branch at NCI to study neurobehavioral and metabolic risk factors for smoking addiction and ability to quit. Over 500 participants in a smoking cessation study and non-smoking controls have been enrolled and blood was collected. Over 100
samples have undergone DNA extraction. We have
developed assays to measure polymorphisms in the D2
dopamine receptor, D4 dopamine receptor and tyrosine
hydroxylase. These candidate polymorphisms have been
linked to altered neurotransmitter levels, addictive
behavior or psychiatric abnormalities. Thus, we will
ask the question if women with specific psychological
profiles (i.e., depression) and genetic polymorphisms
have a greater risk for addiction and a decreased
chance of quitting.

CONCLUSIONS

The findings of an association of smoking and breast cancer
in Caucasian women with the slow NAT2 acetylation genotype is
very important because approximately 50% of women are slow
acetylators. This results in a large attributable risk. The
findings need to be reproduced and examined in other races. We
are currently doing that. Laboratory studies also need to
corroborate this finding by examining the metabolic potential in
rapid and slow acetylators. We also are currently doing this.
The finding that cultured breast cells metabolize 4-aminobiphenyl
indicates that we will be able to address the question directly
about the role of this carcinogen in breast cancer.

Although less striking, the findings of increased risk in
NAT2 rapid acetylators who eat processed meats also is important.
The results suggest that heterocyclic amines play a role in
breast cancer, as suggested by laboratory studies. Studies that
can specifically develop an index of heterocyclic amine exposure
are needed.

The lack of associations for the CYP2E1 is important as
other investigators are planning to study this gene. The
negative findings might lead some investigators to devote their
resources elsewhere or utilize different study designs that might
still elucidate a role for this polymorphism.

It is too early to make conclusions for the other studies as
the assays and analyses are not completed.

Thus far, the findings of these studies are important
because they are identifying new etiologies for breast cancer
where behavior modification would lead to a decreased risk.
REFERENCES


